drugset / Trial / NCT00260351
Immunogenicity and Safety of Verorab™ in Indian Population
RandomizedParallel-groupOpen-labelTreatment
Summary
* To demonstrate that rabies vaccine administered according to the Thai Red Cross, (TRC)-ID regimen (2-2-2-0-1-1) is not inferior to rabies vaccine administered according to the ESSEN IM regimen in terms of Geometric Mean Titers (GMTs) at D28, in subjects with a WHO category III rabies exposure,or, * To demonstrate that Rabies vaccine administered according to the ZAGREB-IM regimen (2-1-1) is not inferior to Rabies vaccine administered according to the ESSEN IM regimen in terms of GMTs at D28, in subjects with a WHO category III rabies exposure. Secondary objectives: 1. To describe the immunogenicity profile of each regimen 2. To assess the safety of the vaccine in each group.
Timeline
- Start
- 2004-12
- Primary completion
- 2008-08
- Completion
- 2008-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Purified Verocell Rabies Vaccine | Vaccine | 0.1 ml | Other |
| Subject | Purified Verocell Rabies Vaccine | Vaccine | 0.5 ml | Other |